Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very low-dose naloxone added to ropivacaine for axillary block in hand and forearm surgery
IRCT20170105031787N6Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of naloxone and ropivacaine in pain (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pain score and Amount of drug use. Started May 2023; status: completed.
02
Drugs
naloxoneropivacaine
03
Conditions
pain
Beyond the preview
Go deeper on IRCT20170105031787N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170105031787N6.